Security National Bank Invests $82,000 in GSK plc (NYSE:GSK)

Security National Bank bought a new position in shares of GSK plc (NYSE:GSKFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,203 shares of the pharmaceutical company’s stock, valued at approximately $82,000.

A number of other institutional investors have also made changes to their positions in GSK. Versant Capital Management Inc increased its stake in shares of GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the last quarter. BKM Wealth Management LLC bought a new stake in shares of GSK in the fourth quarter worth $32,000. Jones Financial Companies Lllp increased its stake in shares of GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares during the last quarter. Princeton Global Asset Management LLC increased its stake in shares of GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock worth $56,000 after buying an additional 533 shares during the last quarter. Finally, Armstrong Advisory Group Inc. increased its stake in shares of GSK by 189.1% in the fourth quarter. Armstrong Advisory Group Inc. now owns 1,619 shares of the pharmaceutical company’s stock worth $60,000 after buying an additional 1,059 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Finally, The Goldman Sachs Group initiated coverage on shares of GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Read Our Latest Stock Report on GSK

GSK Stock Performance

GSK stock traded down $0.33 during trading on Friday, hitting $41.21. 3,025,354 shares of the company’s stock traded hands, compared to its average volume of 4,173,385. The stock has a fifty day moving average price of $42.61 and a two-hundred day moving average price of $40.70. The stock has a market capitalization of $85.41 billion, a price-to-earnings ratio of 14.93, a price-to-earnings-growth ratio of 1.26 and a beta of 0.66. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92.

GSK (NYSE:GSKGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. As a group, equities analysts anticipate that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.65%. This is a positive change from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio is currently 53.26%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.